WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522410
Description: Adriforant, also known as ZPL-3893787, PF-3893787 and ZPL-389, is a novel histamine H4 receptor antagonist. Adriforant shows an excellent in vitro profile that warrants their further investigation in relevant models of human disease. Histamine H4 receptor (H4R) has become a promising target for immuno-inflammatory diseases, such as allergic rhinitis, asthma or dermal allergies.
MedKoo Cat#: 522410
Chemical Formula: C13H22N6
Exact Mass: 262.19059
Molecular Weight: 262.36
Elemental Analysis: C, 59.51; H, 8.45; N, 32.03
Adriforant is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: ZPL-3893787; ZPL3893787; ZPL 3893787; ZPL-389; ZPL 389; ZPL389; PF-03893787; PF03893787; PF 03893787; PF-3893787; PF3893787; PF 3893787; Adriforant;
IUPAC/Chemical Name: (R)-N4-(cyclopropylmethyl)-6-(3-(methylamino)pyrrolidin-1-yl)pyrimidine-2,4-diamine
InChi Key: ISBHYKVAFKTATD-SNVBAGLBSA-N
InChi Code: InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1
SMILES Code: NC1=NC(N2CC[C@@H](NC)C2)=CC(NCC3CC3)=N1
The following data is based on the product molecular weight 262.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Andaloussi M, Lim HD, van der Meer T, Sijm M, Poulie CB, de Esch IJ, Leurs R,
Smits RA. A novel series of histamine H4 receptor antagonists based on the
pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence
time with PF-3893787. Bioorg Med Chem Lett. 2013 May 1;23(9):2663-70. doi:
10.1016/j.bmcl.2013.02.091. Epub 2013 Mar 1. PubMed PMID: 23558237.
2: Salcedo C, Pontes C, Merlos M. Is the H4 receptor a new drug target for
allergies and asthma? Front Biosci (Elite Ed). 2013 Jan 1;5:178-87. Review.
PubMed PMID: 23276980.
3: Mowbray CE, Bell AS, Clarke NP, Collins M, Jones RM, Lane CA, Liu WL, Newman
SD, Paradowski M, Schenck EJ, Selby MD, Swain NA, Williams DH. Challenges of drug
discovery in novel target space. The discovery and evaluation of PF-3893787: a
novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov
1;21(21):6596-602. doi: 10.1016/j.bmcl.2011.07.125. Epub 2011 Aug 9. PubMed PMID: